ERBB2 and breast cancer: Patients with luminal B-like (HER2 positive) BC should receive cytotoxics, anti-HER2 and endocrine therapy; patients with HER2 positive (non-luminal) BC should receive cytotoxics and anti-HER2 and patients with triple negative (basal-like) BC should be treated with cytotoxics.